Abstract
TLR ligands that mimic pathogen associated molecular patterns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses.
MeSH terms
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Antibody Formation / drug effects
-
Antibody Formation / immunology
-
Cytokines / metabolism
-
Female
-
Hepatitis Antibodies / analysis
-
Hepatitis Antibodies / biosynthesis
-
Hepatitis B Surface Antigens / immunology
-
Imidazoles / pharmacology*
-
Immunity, Cellular / drug effects
-
Immunity, Cellular / immunology
-
Immunization
-
Interferon-gamma / metabolism
-
Mice
-
Mice, Inbred BALB C
-
Oligodeoxyribonucleotides / pharmacology*
-
T-Lymphocytes, Cytotoxic / immunology
-
Toll-Like Receptors / agonists*
Substances
-
Adjuvants, Immunologic
-
CPG-oligonucleotide
-
Cytokines
-
Hepatitis Antibodies
-
Hepatitis B Surface Antigens
-
Imidazoles
-
Oligodeoxyribonucleotides
-
Toll-Like Receptors
-
Interferon-gamma
-
resiquimod